Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 5:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 281 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo 50 or 100 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

NCT03082235
View directory record Official record
Conditions
Healthy Participants
Interventions
E6742, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation

NCT04310579
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

NCT01740791
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
Velpatasvir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Bethanechol on Glucose Homeostasis

NCT01434901
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, Bethanechol (25 mg), Bethanechol (50 mg), Bethanechol (100 mg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 10, 2026, 5:19 PM EDT
Not listed Phase 3 Interventional

A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients

NCT02605434
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa, Sinemet®, Placebo -AP-CD/LD, Placebo- Sinemet
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

NCT02511431
View directory record Official record
Conditions
Hepatitis D
Interventions
Lonafarnib, Ritonavir, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

Vitamin C & Thiamine to Treat Sepsis and Septic Shock

NCT03592277
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Vitamin C, Vitamin B1
Drug
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

NCT00976937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 3 Interventional

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

NCT00627640
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinimide 50-100 mg/day, Matching Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 10, 2026, 5:19 PM EDT
Recruiting Phase 2 Interventional

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

NCT06406114
View directory record Official record
Conditions
Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

NCT02165267
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, SC placebo for VRC01, IV placebo for VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 10, 2026, 5:19 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Oral MG001

NCT07204171
View directory record Official record
Conditions
Safety and Tolerability in Healthy Subjects
Interventions
mitragynine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Not applicable Interventional Results available

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

NCT01433055
View directory record Official record
Conditions
Schizophrenia
Interventions
Minocycline, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

NCT01081821
View directory record Official record
Conditions
Healthy
Interventions
single dose NJ-39758979/ matching placebo, multi-dose JNJ-39758979 /matching placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

NCT03450187
View directory record Official record
Conditions
Bacterial Infections
Interventions
TP-271
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 4 Interventional Results available

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

NCT00419003
View directory record Official record
Conditions
Major Depression
Interventions
Lamotrigine, Ketamine, Riluzole
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 10, 2026, 5:19 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

VK4-116 Phase I Study With Food-Effect

NCT06808932
View directory record Official record
Conditions
Opioid Dependence, Opioid Use Disorder (OUD)
Interventions
VK4-116, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 2 Interventional Results available

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

NCT02676466
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo)
Dietary Supplement · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
70 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

NCT02163694
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
56
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

NCT03218969
View directory record Official record
Conditions
Restless Legs Syndrome, Augmentation
Interventions
Ecopipam, Placebo
Drug
Lead sponsor
William Ondo, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

NCT02475317
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Maralixibat, Volixibat
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 10, 2026, 5:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

NCT02889367
View directory record Official record
Conditions
Healthy
Interventions
Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 10, 2026, 5:19 PM EDT